Summary
The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) Study is a double-blind, placebo-controlled, Phase 3 study designed to test whether an investigational anti-amyloid antibody (solanezumab) can slow the progression of memory problems associated with brain amyloid. The screening pre-randomization cognitive, behavioral, questionnaire and quantitative imaging data are available in the LONI IDA. Full study data is available at https://a4studydata.org/
About This Data Partner
The A4 Study is a public-private partnership, funded by the NIA, Eli Lilly and Company, and several philanthropic organizations, including the Alzheimer's Association and GHR Foundation. The A4 Study is coordinated by USC's Alzheimer's Therapeutic Research Institute (ATRI), with study sites in the US, Canada, Australia, and Japan. The full A4/LEARN study data is available at https://www.a4studydata.org/. The full A4 Study Team listing is available at https://www.actcinfo.org/a4-study-team-lists/.
Additional Information
Principal Investigator(s)
Reisa Sperling, MD and Paul Aisen, MD
Data Available
Pre-randomization cognitive testing, behavioral, clinical and questionnaire data, imaging (amyloid PET, tau PET, structural and functional MRI), and biospecimens (plasma, DNA).
The Global Alzheimer's Association Interactive Network